Abstrakti

Cancer immunotherapy has revolutionized the way tumors are treated. Nevertheless, efficient and robust testing platforms are still missing, including clinically relevant human ex vivo tumor assays that allow pretreatment testing of cancer therapies and selection of the most efficient and safe therapy for a specific patient. In the case of immunotherapy, this testing platform would require not only cancer cells, but also the tumor microenvironment, including immune cells. Here, we discuss the applications of patient-derived tumor organoid cultures and the possibilities in using complex immune-organoid cultures to provide preclinical testing platforms for precision cancer immunotherapy.

Alkuperäiskielienglanti
LehtiCancer Research
Vuosikerta81
Numero12
Sivut3149-3155
Sivumäärä7
ISSN0008-5472
DOI - pysyväislinkit
TilaJulkaistu - 15 kesäkuuta 2021
OKM-julkaisutyyppiA2 Katsausartikkeli tieteellisessä aikakauslehdessä

Tieteenalat

  • 3122 Syöpätaudit

Siteeraa tätä